What is Create Medic Co., Ltd. stock?

Create Medic Co., Ltd. Business Introduction

Create Medic Co., Ltd. (Tokyo Stock Exchange: 5187) is a specialized Japanese medical device manufacturer primarily focused on the development, production, and sale of single-use silicone-based medical devices. Since its inception, the company has carved out a niche in the healthcare sector by specializing in minimally invasive treatment tools and catheters.

Business Summary

Create Medic operates as a comprehensive medical technology firm that manages the entire lifecycle of its products, from R&D to manufacturing and clinical support. Its product portfolio is centered on "silicone technology," leveraging the material's biocompatibility to create devices used in urology, gastroenterology, and anesthesiology. As of the fiscal year ending December 2023, the company reported consolidated net sales of approximately 12.8 billion JPY, maintaining a stable financial position with a focus on high-quality "Made in Japan" medical solutions.

Detailed Business Modules

1. Urology & Drainage: This is the company's foundational segment. It includes specialized urinary catheters (balloon catheters) for long-term placement and drainage kits. They are known for their proprietary silicone formulations that reduce the risk of encrustation and infection.
2. Gastroenterology: A significant growth driver for the company. Key products include Percutaneous Endoscopic Gastrostomy (PEG) kits, which are used to provide nutrition to patients who cannot swallow. Their "GB Button" and related gastrostomy tubes are market leaders in Japan.
3. Endovascular & IVR (Interventional Radiology): Create Medic produces micro-catheters and guide wires used in vascular treatments. These products assist physicians in navigating complex vascular structures to deliver localized treatments.
4. Anesthesiology & Nursing Care: This involves specialized tubes for airway management and general nursing supplies designed to improve patient comfort and reduce the workload of healthcare providers.

Business Model Characteristics

Silicone Specialization: Unlike diversified giants, Create Medic focuses almost exclusively on silicone, which is highly biocompatible and flexible. This specialization allows for deeper expertise in material science for medical applications.
In-house Production: The company maintains its own factories (notably in Japan and Vietnam), ensuring strict quality control and the ability to customize products based on feedback from clinical professionals.
Clinical Feedback Loop: The company employs a "User-Driven" development model, where sales representatives and engineers work directly with hospital physicians to iterate on device designs.

Core Competitive Moat

Regulatory Barriers: The medical device industry is characterized by stringent PMDA (Japan) and international certifications. Create Medic’s decades of compliance history and established clinical data form a significant barrier to new entrants.
Physician Loyalty: In the medical field, switching costs are high. Surgeons and nurses who are trained on specific Create Medic PEG kits or catheters often prefer to stick with known ergonomic designs, creating a "locked-in" customer base.
Advanced Silicone Processing: The ability to extrude and mold silicone into extremely thin, multi-lumen catheters with high precision is a technical hurdle that few competitors can match at scale.

Latest Strategic Layout

Under its current medium-term management plan, Create Medic is focusing on two main pillars: Global Expansion and Product Innovation. The company is aggressively expanding its footprint in the Southeast Asian market via its Vietnamese production base and seeking increased regulatory approvals in the US and EU markets. Furthermore, they are investing in "Smart Medical" initiatives, exploring the integration of sensors into catheters for real-time patient monitoring.

Create Medic Co., Ltd. Development History

The history of Create Medic is a journey of transition from a small-scale laboratory to a publicly traded international medical device provider, characterized by a persistent focus on silicone technology.

Development Phases

Phase 1: Foundation and Specialization (1974 - 1980s)
Founded in 1974 in Yokohama, the company initially focused on the potential of silicone as a medical material. At a time when PVC was common, Create Medic bet on the superior safety profiles of silicone. In 1978, they successfully developed the first all-silicone balloon catheter in Japan, establishing their technical credibility.

Phase 2: Product Diversification and Domestic Growth (1990s - 2004)
During this period, the company expanded beyond urology into gastroenterology. The launch of their PEG (Percutaneous Endoscopic Gastrostomy) products coincided with Japan’s aging population, leading to a surge in demand for long-term nutritional care solutions. In 1996, the company went public on the JASDAQ market (later moving to the Tokyo Stock Exchange).

Phase 3: International Expansion and Capacity Building (2005 - 2018)
To optimize costs and serve the global market, Create Medic established "Create Medic Vietnam Co., Ltd." in 2010. This facility became a cornerstone for their global supply chain. During this stage, they also enhanced their R&D centers in Japan to focus on high-value-added interventional radiology (IVR) products.

Phase 4: Digital Transformation and Global Consolidation (2019 - Present)
The company is currently navigating the post-pandemic landscape by digitizing its sales processes and focusing on "high-end" minimally invasive devices. It is also restructuring its portfolio to meet the new EU Medical Device Regulation (MDR) standards to ensure continued access to European markets.

Analysis of Success Factors

Early Adoption of Silicone: By identifying the limitations of latex and PVC early on, they secured a "first-mover" advantage in the high-end silicone catheter market.
Focus on the Aging Society: Their strategic pivot toward gastrostomy and urology perfectly aligned with Japan’s demographic shift, providing a recession-proof revenue stream.
Quality Consistency: By maintaining a significant portion of manufacturing in Japan and under strict Japanese management in Vietnam, they avoided the quality pitfalls that often plague low-cost medical manufacturers.

Industry Introduction

Create Medic operates within the Global Medical Device Industry, specifically the "Consumables and Minimally Invasive Surgery" segment. This industry is valued at hundreds of billions of dollars globally and is characterized by steady growth driven by demographic changes.

Industry Trends and Catalysts

1. Aging Population (Silver Democracy): In markets like Japan, Europe, and China, the increasing number of elderly citizens drives demand for chronic care devices (catheters, PEG kits).
2. Shift to Minimally Invasive Surgery (MIS): There is a global trend toward reducing hospital stay times. Create Medic’s catheters and IVR tools are essential for MIS, which requires smaller incisions and faster recovery.
3. Home Healthcare: There is a rising shift from hospital-based care to home-based care. Devices that are "user-friendly" for caregivers (like Create Medic’s PEG buttons) are seeing increased adoption.

Industry Data Overview

Competitive Landscape

The industry is split between "Global Giants" and "Niche Specialists."
Global Giants: Companies like Terumo, B. Braun, and Bard (BD) compete in the high-volume commodity and complex cardiovascular segments. They have massive distribution networks but may lack the specialized "hand-crafted" precision for niche silicone applications.
Niche Specialists: This is where Create Medic resides. Their competition includes smaller European and Japanese firms specializing in endoscopy and urology. Create Medic distinguishes itself through its vertically integrated silicone processing and strong relationships with Japanese university hospitals.

Industry Position and Characteristics

Create Medic is regarded as a top-tier specialist in the Japanese medical silicone market. While its total revenue is smaller than conglomerates like Terumo, its market share in specific segments like PEG buttons in Japan is dominant. The company is characterized by a high equity ratio (often exceeding 80%), indicating extreme financial stability and a conservative but steady growth trajectory. In the "Global Niche Top" category, Create Medic is a textbook example of a Japanese firm that dominates a specialized technical field through incremental innovation and high-quality standards.

Create Medic Co., Ltd. Financial Health Score

Create Medic Co., Ltd. (TYO: 5187) is a prominent Japanese medical device manufacturer specializing in silicone catheters and related disposable medical products. Based on the most recent financial data from the fiscal year ending December 31, 2025, and the Q1 2026 report, the company maintains a robust balance sheet characterized by high capital adequacy and low debt.

Note: Financial data is based on the consolidated results for the fiscal year ended December 31, 2025, and interim reports released in May 2026. The high stability score reflects the company's "net cash" position and significant equity ratio, while profitability ratings are tempered by rising cost-of-sales ratios due to currency effects.

Create Medic Co., Ltd. Development Potential

Strategic Roadmap: Global Expansion and "Vision 2034"

Create Medic has launched a long-term strategic plan with a clear focus on diversifying its revenue streams away from domestic markets. The company's "Vision 2034" aims to increase the overseas sales ratio from 33.8% (2025) to 50.0% by 2034. This is supported by a multi-phase growth strategy where 2025–2027 focuses on foundation building and investment in high-growth emerging markets.

Major Catalyst: The Indian Subsidiary and Manufacturing Hub

In April 2026, the company achieved a major milestone by establishing its dedicated sales subsidiary, Create Medic India Pvt. Ltd., in Chennai.
Key milestones in India include:

• Direct Sales Transition: Moving from a distributor model to direct sales to capture higher margins.
• Manufacturing Potential: Plans to invest roughly 20 crore INR in the short term, with a long-term plan to establish a manufacturing plant in India to serve as a supply base for Africa and neighboring Asian countries.
• Market Penetration: Targeting expansion into Mumbai, Delhi, and Ahmedabad within five years.

New Product Catalysts and Aging Demographics

As a specialist in urology and gastroenterology, Create Medic is a primary beneficiary of the super-aging society in Japan and other developed nations. In 2026, the company plans to bolster domestic sales by launching three new specialized products. The rising demand for chronic care and minimally invasive surgery (which reduces patient burden) aligns perfectly with the company's core silicone catheter technology.

Create Medic Co., Ltd. Benefits and Risks

Investment Benefits

1. Strong Shareholder Return Policy: The company recently revised its dividend policy to target a 50% consolidated payout ratio. For the 2026 fiscal year, it plans to increase the annual dividend to 47 yen per share, marking a steady upward trend in income for investors.
2. Exceptional Financial Soundness: With an equity ratio exceeding 80% and significant cash reserves (often exceeding its market capitalization in "net cash" terms), the company is highly resilient to economic downturns and has the capital to fund acquisitions or buybacks.
3. High-Quality Niche Market Position: Create Medic was the first to commercialize all-silicone Foley catheters in Japan. Its specialized manufacturing technology in silicone rubber provides a competitive moat in high-safety-requirement medical fields.

Potential Risks

1. Currency and Exchange Rate Volatility: Recent Q1 2026 data showed a 36.6% decline in operating profit despite rising sales. This was largely attributed to higher cost-of-sales ratios driven by the depreciation of the yen affecting imported goods and materials.
2. Regulatory Hurdles (MDR): Sales in certain segments, such as gastroenterology, have faced pressure due to the impact of Medical Device Regulation (MDR) compliance in international markets, which can delay product launches or increase administrative costs.
3. Front-Loaded Investment Costs: The aggressive expansion into India and the upgrade of internal systems are part of a medium-term plan that involves significant "front-loading" of expenses. This may lead to suppressed short-term earnings growth while the company builds its global infrastructure.

分析师们如何看待Create Medic Co., Ltd.公司和5187股票？

进入2026年，分析师对Create Medic Co., Ltd.（东京证券交易所代码：5187）的看法呈现出“基本面稳健、中长期增长潜力与短期盈利波动并存”的态势。作为一家深耕导管技术的专业医疗器械制造商，Create Medic在2025财年实现了显著的利润反弹，并正处于其“2025-2034中长期管理计划”的起始阶段。

以下是根据最新财务披露（截至2026年5月）和市场分析整理的主流观点：

1. 机构对公司的核心观点

全球化扩张与战略转型： 分析师普遍关注公司向“全球医疗器械制造商”转型的决心。根据其最新的十年计划，公司目标在2034年将海外销售额比例提升至50%（2025财年约为33.8%）。2026年4月，公司在印度成立销售子公司（Create Medic India Pvt. Ltd.），这一举动被视为其加速布局高增长新兴市场的关键一步。

盈利修复与产品结构优化： 2025财年，公司营业利润同比增长45.1%，达到10.05亿日元。分析师指出，利润的增长主要得益于高毛利自产产品（特别是泌尿外科新产品）在日本市场的强劲表现，以及OEM业务的恢复。尽管2026年第一季度因研发投入和成本增加导致营业利润同比下降36.6%（至1.4亿日元），但分析师认为这是由于处于战略投资期，符合其“Phase I：基础建设”阶段的预期。

极高的财务安全性： 公司的资本充足率（Equity Ratio）长期保持在80%以上（截至2026年3月底为84.0%）。这种近乎“无债经营”的稳健财务结构，使得公司在宏观环境波动时具备极强的抗风险能力，也是分析师给予其“防御性避风港”评价的核心原因。

2. 股票评级与目标价

由于Create Medic属于中小型市值（约108.7亿日元）股票，其覆盖范围主要集中在专业医疗行业分析师和量化研究机构：

技术指标评级： 截至2026年5月，根据Investing.com及相关平台的综合技术分析，基于日线级别移动平均线（MA）的表现，该股常被标记为“强烈买入”或“买入”状态。特别是在1100-1200日元区间，由于市净率（P/B）仅约0.6倍，处于显著被低估的状态。

股息与回报预期：分红计划： 公司计划将2026财年的年度股息提高至每股47日元（较2025年增加2日元），目标派息率维持在50%左右。股息收益率： 基于当前约1149日元的股价，其股息收益率约在3.8%至4.1%之间，这对偏好稳定收入的价值投资者具有较强吸引力。股票回购： 公司在2026年3月授权了新的股份回购计划，分析师认为这体现了管理层对提振每股收益（EPS）和资本效率的积极态度。

3. 分析师眼中的风险点（看空理由）

尽管长期前景向好，分析师也提醒投资者注意以下潜在压力：

短期成本压力： 为了实现2034年的宏观目标，公司在2025-2027年间的研发（R&D）和海外渠道建设投入将保持在高位，这可能在短期内压制净利润增长，2026年Q1的利润下滑已初显此趋势。

汇率与供应链风险： 作为一个在越南和中国拥有生产基地且海外销售占比不断扩大的企业，日元汇率的剧烈波动会直接影响其合并利润报表。同时，原材料成本的上升仍是其毛利率能否持续改善的不确定因素。

市场竞争： 尽管在全硅导管等细分领域有优势，但在全球范围内仍面临大型跨国医疗器械巨头的直接竞争，特别是在高端微创介入领域。

总结

华尔街与日本本土分析师的一致看法是：Create Medic（5187）是一家具备“深厚护城河、极高安全性、低估值”特征的医疗标的。 尽管2026年初步业绩受到投资成本增加的影响，但只要其海外扩张步伐稳健，且核心泌尿/消化道产品持续渗透，其目前的低P/B估值水平提供了较高的安全边际，是追求稳定股息和长期资产增值的理想配置选择。

Create Medic Co., Ltd. (5187) Frequently Asked Questions

What are the investment highlights of Create Medic Co., Ltd., and who are its main competitors?

Create Medic Co., Ltd. is a specialized Japanese manufacturer focusing on single-use medical devices, particularly silicone catheters and drainage tubes. Its primary investment highlights include a niche market dominance in specialized medical consumables and a robust R&D pipeline focused on minimally invasive treatments. The company benefits from a high barrier to entry due to stringent medical regulations and its proprietary silicone processing technology.
Major competitors include global medical giants and domestic peers such as Terumo Corporation (4543), Nipro Corporation (8086), and JMS Co., Ltd. (7702). Unlike diversified conglomerates, Create Medic maintains a competitive edge through its high specialization in urology and gastroenterology products.

Is the latest financial data for Create Medic Co., Ltd. healthy? How are the revenue, net income, and debt levels?

Based on the financial results for the fiscal year ended December 31, 2023, and the first half of 2024, Create Medic maintains a stable financial position. For FY2023, the company reported net sales of approximately 12.5 billion JPY, reflecting steady demand in the healthcare sector. Net income has remained positive, supported by cost-management initiatives despite rising raw material prices.
The company's balance sheet is characterized by a high equity ratio (often exceeding 70%), indicating a very low level of interest-bearing debt. This "debt-free" management style provides significant financial resilience against market volatility.

Is the current valuation of Create Medic (5187) high? How do the P/E and P/B ratios compare to the industry?

As of mid-2024, Create Medic (5187) typically trades at a Price-to-Earnings (P/E) ratio in the range of 12x to 15x, which is generally lower than the average for the "Precision Instruments" or "Medical Equipment" sector in Japan, which often sees P/E ratios above 20x.
Its Price-to-Book (P/B) ratio often hovers around 0.7x to 0.9x. A P/B ratio below 1.0 suggests that the stock may be undervalued relative to its net assets, a common characteristic of stable, cash-rich Japanese small-cap companies. Compared to peers like Terumo, Create Medic trades at a significant valuation discount.

How has the stock price performed over the past three months and year? Has it outperformed its peers?

Over the past year, Create Medic's stock price has shown moderate stability with low volatility. While it has not experienced the aggressive growth seen in high-tech or AI-related sectors, it has provided steady returns through consistent dividends.
Compared to the TOPIX or the Nikkei 225, the stock tended to underperform during major bull runs but showed better-than-average defensive qualities during market corrections. Against direct peers in the medical consumables space, its performance has been largely in line with the industry average, reflecting the mature nature of the medical tube market.

Are there any recent positive or negative news trends in the industry affecting Create Medic?

Positive: The global shift toward minimally invasive surgery (MIS) continues to drive demand for the company’s specialized catheters. Additionally, the weakening Yen has benefited the company’s overseas sales margins, particularly in Southeast Asian markets where they have manufacturing bases (e.g., Vietnam).
Negative: The industry faces ongoing pressure from revisions in medical reimbursement prices by the Japanese government, which can squeeze profit margins on domestic sales. Rising costs for medical-grade silicone and logistics also remain a headwind for the manufacturing sector.

Have any major institutions recently bought or sold Create Medic (5187) shares?

Create Medic is primarily held by domestic Japanese institutions and "cross-shareholding" partners. Major shareholders include The Master Trust Bank of Japan and various regional banks. While it does not typically see massive swings from global hedge funds due to its smaller market capitalization, there has been a steady interest from value-oriented investment trusts attracted by the company’s high dividend payout ratio (often targeted at 30% or higher) and its "value trap" potential given the low P/B ratio. Recent filings show stable institutional ownership with no significant mass liquidations.